# Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch

> **NCT04892654** · PHASE3 · RECRUITING · sponsor: **Chelsea and Westminster NHS Foundation Trust** · enrollment: 150 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Doravirine
- **DRUG:** Dolutegravir
- **OTHER:** Triple cART regimen

## Key facts

- **NCT ID:** NCT04892654
- **Lead sponsor:** Chelsea and Westminster NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-17
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04892654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04892654, "Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04892654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*